


This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

Claims 1 to 18 (*cancelled*)

19. (*currently amended*) A method of treating a subject suffering from a condition selected from obesity, ~~eating disorders~~, anorexia nervosa, bulimia nervosa, vasomotor flushing, ~~cocaine addiction~~, alcohol addiction, and ~~sexual dysfunction~~ premature ejaculation, comprising the step of:

providing to said subject suffering from said condition a therapeutically effective amount of a compound of formula I:



I

wherein

R<sup>1</sup> is selected from hydrogen, hydroxy, halo, cyano, carboxamide, carboalkoxy of 2 to 6 carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>6</sup> are independently selected from hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, and alkanoyloxy of 2 to 6 carbon atoms;

R<sup>5</sup> is hydrogen or alkyl of 1 to 6 carbon atoms;

X is CR<sub>6</sub> or N;

a dotted line represents an optional double bond;

(O) represents optional oxidation; and

n is an integer 0, 1, or 2;  
or a pharmaceutically acceptable salt thereof.

20. *(previously presented)* A method according to claim 19, wherein said eating disorder is anorexia nervosa or bulimia nervosa.
21. *(previously presented)* A method according to claim 19, wherein said subject is a human.
22. *(previously presented)* A method according to claim 19, wherein R<sup>1</sup> is hydrogen.
23. *(previously presented)* A method according to claim 19, wherein R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are independently selected from hydrogen, halogen, and cyano.
24. *(previously presented)* A method according to claim 19, wherein R<sup>5</sup> is hydrogen or lower alkyl.
25. *(previously presented)* A method according to claim 19, wherein X is CR<sup>6</sup>.
26. *(previously presented)* A method according to claim 19, wherein R<sup>6</sup> is hydrogen, halo, or cyano.
27. *(previously presented)* A method according to claim 19, wherein  
R<sup>1</sup> is attached to the 6-position of the 1,4-dioxino[2,3-b]pyridine and is hydrogen, hydroxy, halo, cyano, trifluoromethyl, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms;  
R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are independently selected from hydrogen, halo, cyano, alkyl of 1 to 6 carbon atoms, and alkoxy of 1 to 6 carbon atoms;  
n is the integer 0 or 1; or  
a pharmaceutically acceptable salt thereof.

28. **(previously presented)** A method according to claim 27, wherein  
R<sup>6</sup> is hydrogen, halo, or cyano.
29. **(previously presented)** A method according to claim 19, wherein  
R<sup>1</sup> is attached to the 6-position of the 1,4-dioxino[2,3-b]pyridine and is  
hydrogen, hydroxy or alkoxy of 1 to 6 carbon atoms;  
R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are independently selected from hydrogen, halo, and cyano;  
R<sup>5</sup> is hydrogen;  
X is CR<sup>6</sup>;  
N is 0; and  
the dotted line represents a double bond; or  
a pharmaceutically acceptable salt thereof.
30. **(previously presented)** A method according to claim 19, wherein said compound is 3-  
{[4-(1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl}-2,3-  
dihydro[1,4]dioxino[2,3-b]pyridine or a pharmaceutically acceptable salt thereof.
31. **(previously presented)** A method according to claim 19, wherein said compound is 3-  
{[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl}-2,3-  
dihydro[1,4]dioxino[2,3-b]pyridine or a pharmaceutically acceptable salt thereof.
32. **(previously presented)** A method according to claim 19, wherein said compound is 3-  
{1-[2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-ylmethyl]-1,2,3,6-tetrahydro-4-  
pyridinyl}-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
33. **(previously presented)** A method according to claim 19, wherein said compound is 3-  
{[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl}-2,3-  
dihydro[1,4]dioxino[2,3-b]pyridine or a pharmaceutically acceptable salt thereof.